Interleukin-2trial

[Nikki J]

Mixed but hopeful results in a large and long phase 2 trial. It did not meet the primary endpoint but there was a significant survival difference between those who received drug and placebo in the pre specified slow progression group( defined by csf nfh levels. ). You will see at the end they suggest another trial might explore a more aggressive treatment to see if it could also help the fast progression group.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00262-4/fulltext?fbclid=IwY2xjawKMh_FleHRuA2FlbQIxMQBicmlkETE0MUJVRzRlRGt3T0RsTmtoAR4qpKdN25OCgwcS4QZGS1Iewil5uGl_CLSC28QeRJudx_usOEB1GgZVDObBFw_aem_PGWsE9sqae1Cmnp7_x4R-Q

 

[SpeedyMarie]

I was in the phase 1 and gained 11 points on the ALS FR score felt much stronger and some of my symptoms reversed while I was on it. The FDA slowed the second phase hopefully phase 2 gets up and on and phase 3 goes well and it gets out and approved soon. It really does help.

 

[Nikki J]

You were in Coya? How wonderful! This study wasn’t the combination. I wonder if the coya combination will do even better than this

 

[maryna]

Hi,
Has the reversal of the ALSFRC sustained or has it come back after the trial?

 

[csommers]

do they still give it to you after the trial as compassionate use or expanded access? sounds like it really worked well for you!

 

[JAM]

What is Coya

 

[lgelb]

COYA 302, described in this pipeline roundup.